Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TSU-68 (orantinib) in hepatocellular carcinoma treated with TACE
jRCT2080221054Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of orantinib in hepatocellular carcinoma (HCC), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
orantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221054.